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InsulinLeptin is hypothesized to function as a negative feedback signal in the regulation of energy balance. It is
produced primarily by adipose tissue and circulating concentrations correlate with the size of body fat stores.
Administration of exogenous leptin to normal weight, leptin responsive animals inhibits food intake and
reduces the size of body fat stores whereas mice that are deﬁcient in either leptin or functional leptin receptors
are hyperphagic and obese, consistent with a role for leptin in the control of body weight. This review discusses
the effect of leptin on adipocyte metabolism. Because adipocytes express leptin receptors there is the potential
for leptin to inﬂuence adipocyte metabolism directly. Adipocytes also are insulin responsive and receive sympa-
thetic innervation, therefore leptin can also modify adipocyte metabolism indirectly. Studies published to date
suggest that direct activation of adipocyte leptin receptors has little effect on cell metabolism in vivo, but that
leptin modiﬁes adipocyte sensitivity to insulin to inhibit lipid accumulation. In vivo administration of leptin
leads to a suppression of lipogenesis, an increase in triglyceride hydrolysis and an increase in fatty acid and
glucose oxidation. Activation of central leptin receptors also contributes to the development of a catabolic
state in adipocytes, but this may vary between different fat depots. Leptin reduces the size of white fat depots
by inhibiting cell proliferation both through induction of inhibitory circulating factors and by contributing
to sympathetic tone which suppresses adipocyte proliferation. This article is part of a Special Issue entitled:
Modulation of Adipose Tissue in Health and Disease.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Early animal and human studies indicated that mechanisms are in
place to balance energy intake and energy expenditure over periods
of days or weeks [1,2]. This slow, but precise regulation allows the
body weight of an individual to ﬂuctuate around a stable mean [3,4].
Various hypotheses have been put forward as to the feedback signal
that would allow body weight to be controlled including mechanisms
that regulate blood glucose [5], amino acids [6] or body temperature
[7]. In 1953, Kennedy proposed the lipostatic theory [8] in which food
intake is controlled by the hypothalamus to regulate body fat stores
and over time it has become accepted that changes in the body weight
of an adult are primarily determined by changes in body fat mass. This
hypothesis requires that the hypothalamus detects the size of fat stores
and parabiosis studies with hypothalamic obese rats [9] and genetically
obese mice [10] demonstrated the presence of a humoral factor in the
feedback regulation of body fat content. In 1994, Friedman's group
[11] identiﬁed this circulating factor as ob protein which is now more
commonly known as leptin.ion of Adipose Tissue in Health
s University, 1120 15th Street,
fax: +1 706 721 7299.
l rights reserved.1.1. Leptin production
The primary site of leptin production is white adipose tissue [11],
although it is also expressed in several other tissues including the
stomach [12], lungs [13], placenta [14] and possibly the brain [15].
In rodent adipose tissue leptin expression becomes apparent after dif-
ferentiation of preadipocytes to adipocytes coinciding with early
stages of lipid accumulation in the cells [16]. Expression is low during
suckling, but increases rapidly after weaning [17]. The rate of increase
in expression is proportional to white fat mass [18,19] and, although
leptin expression varies between different fat depots [20,21], it shows
a strong correlation with adipocyte size [22]. Leptin is continuously
secreted, however, the rate of secretion may be increased or decreased
independently of regulation of leptin mRNA expression [23] due to the
presence of small vesicular stores of leptin in adipocytes [24,25].
Sustained stimulation of secretion requires a simultaneous increase in
leptin mRNA expression to prevent rapid exhaustion of these leptin
stores [23].
As noted above circulating concentrations of leptin increase in
proportion to the size of white fat depots [18], but release is pulsatile
[26] and there are diurnal oscillations in leptin release independent of
weight related changes in circulating leptin. In humans leptin is
higher at night than during the day [27] and may be entrained by
meal consumption [28,29]. The response to a meal is greater at night
than in the morning, and also correlates with the glycemic index of the
meal [30]. By contrast, fasting [31] or cold exposure [32] inhibit leptin
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fromadipocytes have been linked to insulin stimulation [23], cell glucose
uptake [33] and the availability of energy substrates [34], all of which are
indicative of an anabolic state. Activation of β-adrenergic receptors [35],
or elevation of intracellular cAMP inhibit leptin expression [36] as does
exposure to free fatty acids [37,38], each of which may be indicative of
a state of energy mobilization. Detailed reviews of the regulation of
leptin expression and secretion have been provided by Szkudelski [39]
and by Lee and Fried [40].
1.2. Leptin receptors
There are multiple isoforms of the leptin receptor (ObRa-ObRe)
[41] that have the structure of Class I cytokine receptors [42]. The
different receptor subtypes have different length intracellular sequences
and ObRb is the only receptor that includes binding domains necessary
for JAK-STAT signaling. This long-form receptor (ObRb) has been shown
to activate the transcription factors signal transducer and activator of
transcription (STAT) 1, 3, 5 and 6 [43,44] in addition to phosphorylating
phosphoinositide 3-kinase (PI3K) [45], mitogen activated protein
kinases (MAPK) 1 and 2 [46] and increasing insulin receptor substrate-
1 (IRS-1) and IRS-2-associated PI3K [44]. Disruption of the STAT3 bind-
ing site on ObRb results in hyperphagia, a reduced energy expenditure
and a degree of obesity that is equivalent to that in mice that are deﬁ-
cient in ObRb [47]. Therefore, activation of STAT3 is commonly used as
a marker of leptin receptor activation. ObRa, ObRc, and ObRd have
short intracellular domains and it is suggested that their primary func-
tions are to transport leptin across the blood brain barrier [48] and to
mediate lysosomal degradation of leptin [49]. ObRe is a circulating re-
ceptor that is produced by cleavage of the extracellular domain of both
long and short-form leptin receptors [50,51]. ObRe sequesters leptin in
the circulation [52] and can therefore regulate leptin bioactivity
[53,54]. In lean subjects the amount of leptin that is bound to ObRe pre-
dominates over free leptin [55], butwith the development of obesity the
concentration of free leptin increases while bound leptin does not
change. Brabant et al. [56] reported that free and bound leptin are re-
leased from adipose tissue in proportion to their concentrations in the
circulation, and at least someof the leptin secreted fromadipocytes is al-
ready bound to ObRe.
Leptin receptors are expressed on a majority of tissues and high
concentrations have been identiﬁed in the arcuate nucleus of the
hypothalamus [57], lung, liver, spleen, kidneys, adrenal [58] and repro-
ductive tissues [59]. Lower concentrations have been identiﬁed in
multiple peripheral tissues including adipocytes [60] where receptors
have been detected both as mRNA and long- and short-form protein.
These include hypothalamic nuclei, the raphe nucleus, the hippocam-
pus, the amygdala, the ventral tegmental area, the area postrema and
the nucleus of the solitary tract [57], and many areas of the brain that
contribute to the control of food intake or energy expenditure. Although
the level of leptin receptor expression is low in adipocytes, both mRNA
[61–63] and protein [64–66] have been detected in various species,
demonstrating the presence of long- and short-form receptors [65,66]
which were reported to be located on the cell membrane and in small
cytoplasmic vesicles in adipocytes [64]. Because adipocytes express
leptin receptors [64] and receive sympathetic innervation [67] it is
possible for leptin to have direct effects on adipocyte development
and function, but also to indirectly modify adipocyte metabolism both
through central mechanisms and via modiﬁcation of release and func-
tion of metabolically active hormones, such as insulin.
The expression of ObR on T cells [68], B cells [69], monocytes and
macrophages [70] indicates the potential for leptin to play an important
role in both innate and acquired immune responses, as discussed in
recent reviews [71,72]. Both in vivo [73] and in vitro [74] studies
indicate that leptin has pro-inﬂammatory properties. Of relevance to
this review is that obesity is recognized as a chronic low-grade inﬂam-
matory condition [75] and that pro-inﬂammatory cytokines contributeto the associated development of insulin resistance [76]. Experimental
measures in humans [77] demonstrate a correlation between adipose
tissue leptin expression and markers of inﬂammation, therefore the
environment within obese adipose tissue appears to be one in which
hyperleptinemia has the potential to promote inﬂammation and indi-
rectly inﬂuence adipocyte metabolism.1.3. Leptin resistance
Although the ﬁrst animal experiments clearly demonstrated that
leptin could inhibit food intake and weight gain and reduce body fat
mass in both lean and obese, leptin deﬁcient ob/ob mice [78–80], it
soon became clear that leptin had no effect on food intake or body
composition of animals that expressed leptin receptors, but were
obese and had elevated circulating concentrations of endogenous
leptin [81,82]. This condition is referred to as leptin resistance. More
recently it has been shown that the failure to change food intake in
response to leptin administration may reﬂect the development of
leptin resistance in speciﬁc hypothalamic nuclei [83]. This suggests
that only select actions of leptin are abolished by leptin resistance
and in support of this Enriori et al. [84] reported that leptin continued
to stimulate sympathetic outﬂow to brown fat in diet induced obese
mice that were resistant to the effects of leptin on food intake. In
parallel with the development of central leptin resistance Wang et al.
[85] have proposed that white adipose tissue develops a local leptin
resistance whichmay partially explain why high circulating concentra-
tions of leptin in obese animals have little effect onwhite adipose tissue
mass. They also [86] reported that activation of STAT3 was diminished
in adipose tissue from leptin resistant diet induced obese rats in both
basal and leptin stimulated conditions. The resistance was associated
with an early elevation of suppressor of cytokine signaling (SOCS) 1
and 3 expression, which inhibits activation of JAK/STAT3 [87], followed
by suppression of ObRb expression [86]. Similarly it has been reported
that leptin receptor expression is greatly reduced in adipose tissue
frommorbidly obesewomen [88], but SOCS3 is also suppressed, possibly
because of a reduced need to inhibit cytokine signaling. As discussed
below, although leptin has little direct effect on adipocyte glucose
metabolism, there is evidence for leptin modifying adipocyte insulin
responsiveness [89] and for maintaining basal rates of liploysis [90],
therefore, leptin resistance at the level of the adipocyte may contribute
to changes in the ability of fat cells to regulate triglyceride turnover.
Thus, the development of leptin resistance is more complicated than
just modiﬁcation of leptin transport into the brain [91] or a change in
responsiveness of receptors in speciﬁc brain sites [83,84]. Identifying
factors associated with the development and consequences of leptin
resistance may lead to a better understanding of how leptin inﬂuences
themetabolic and physiologic state of an animal in conditions of obesity.2. Evidence for a direct effect of leptin on adipose tissuemetabolism
The focus of this review is the effect of leptin on adipocyte metabo-
lism. Relatively little has been published related to an investigation of
the effects of leptin on adipocyte metabolism compared with the large
number of studies that have examined the effects of central or peripheral
leptin administration on whole animal energy balance. Adipose tissue
expresses both long- and short-form receptors [60] providing the poten-
tial for self-regulation of leptin expression [92,93] in addition to direct
metabolic effects of leptin on adipocytes. As discussed below, the change
in metabolism may also be achieved indirectly through modiﬁcation of
release of metabolically active hormones, changes in response to these
hormones or by increasing the activity of sympathetic afferents to the
fat cell. Administration of leptin to leptin-responsive animals reduces
body fat mass [94], therefore there must be a shift in the balance
between lipolysis and lipogenesis to favor lipid mobilization.
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In order to demonstrate that leptin acts directly on adipocytes it is
necessary to exclude the involvement of hormonal and neural control
by conducting in vitro and cell culture studies. A limitation of these
studies is that the normal physiologic concentration of leptin in the
local environment of adipocytes is unknown, but can be assumed to
be higher than circulating leptin which is typically in the range of
0.2 to 5 nM (3–80 ng/ml). In vitro studies have tested the ability of
leptin to directly inﬂuence adipocyte metabolism and overall there
appears to be a small direct effect on basal activity of lipogenic and
lipolytic metabolic pathways, but there is more convincing evidence
for leptin inhibiting insulin responsiveness of adipose tissue. Studies
examining glucose uptake by white adipose tissue found no response
to leptin when it was administered centrally [95], intravenously [96]
or directly (30–1000 ng/ml for 30 min) to adipocytes [97]. Similarly,
acute exposure to even high concentrations (800 ng/ml) of leptin on
isolated rat adipocytes had no effect on metabolism although there
was a small increase in basal glucose transport and lipogenesis after
16 h [89]. This prolonged exposure to leptin did, however, cause a sub-
stantial dose dependent inhibition of insulin-stimulated glucose uptake
by the adipocytes [89] and the time taken for loss of sensitivity to insu-
lin was inversely proportional to leptin concentration. Physiological
concentrations of 16 ng/ml (1 nM) leptin caused a signiﬁcant loss of
responsiveness after about 1 h, suggesting that the loss of insulin sensi-
tivity did not result from simply interfering with insulin binding on
its receptor. The inhibition of insulin-dependent glucose uptake is
paralleled by decreases in lipogenesis, esteriﬁcation of lipids, and glyco-
gen synthase activity [89]. Leptin does not inhibit the stimulation of
glucose metabolism by vanadate [89,98], which increases IRS-1 associ-
ated PI3K independent of insulin receptor activation [99], implying
that leptin interferes with an early stage of insulin signaling. In support
of this notion a 45-minute exposure to high concentrations of leptin
(800 ng/ml) has been reported to inhibit insulin binding in isolated rat
adipocytes [100] and a 20-minute exposure to high (80–800 ng/ml),
but not low (8 ng/ml) concentrations of leptin signiﬁcantly increases
adipocyte SOCS3 expression [98], which can potentially inhibit auto-
phosphorylation of the insulin receptor [101] in addition to down-
regulating leptin responsiveness of the cells [102]. Leptin also inhibits
activation of the signaling proteins MAPK and GSK3 in isolated adipo-
cytes, although it has no effect on basal levels of activation of these
proteins [98].
In addition to suppressing insulin-stimulated glucose metabolism,
leptin has been shown to directly inhibit lipid synthesis. Adipocytes
exposed to physiological concentrations of leptin (20 ng/ml) show a
time-dependent suppression of fatty acid synthetase expression such
that there is a 90% inhibition after 24 h [103]. This inhibition of enzyme
activity also has been reported for cultured 30A5 preadipocytes in
which there was a leptin-dependent inhibition of insulin stimulated
acetyl co-A carboxylase expression and lipid synthesis [104]. Concur-
rentwith the suppression of lipogenic enzymes is an increase in expres-
sion of enzymes associated with fatty acid oxidation [103,105],
increased fatty acid oxidation [105] and increased glucose oxidation
due to a stimulation of citrate synthase expression and activity of the
citric acid cycle [105,106]. Transcriptional control of enzymes required
for mitochondrial fatty acid oxidation is regulated by the fatty acid-
activated nuclear receptor peroxisome proliferator-activated receptor
alpha (PPARα) [107] and exposure of isolated adipocytes to leptin for
6 h stimulates the expression of PPARγ coactivator-1 (PGC-1) [108], a
coactivator that is required for activation of PPARα [109].
2.2. Direct effect on lipolysis
A more detailed examination of the effects of leptin on fatty acid
metabolism in isolated rat adipocytes [110] showed that a 6-hour
exposure to 10 ng/ml leptin inhibited basal and insulin-stimulatedrates of de novo fatty acid synthesis from glucose. By contrast, leptin
stimulated fatty acid esteriﬁcation to triglycerides, and also caused an
even greater increase in hydrolysis so that there was a net efﬂux of
fatty acids from the cells. Interestingly, fatty acid oxidation was only
increased when fatty acids were present in the incubation media
and tracking the fate of fatty acids released from triglycerides showed
that they were released from the cell, suggesting that leptin had
differential effects on the metabolism of different pools of fatty acid
substrate [110]. Recently it has also been reported that leptin stimu-
lates the production of nitric oxide which in turn inhibits glycerol
synthesis, reducing the opportunity for fatty acid re-esteriﬁcation in
adipocytes [111]. Thus, leptin inhibits accumulation of lipid in adipo-
cytes by increasing the turnover of triglycerides, inhibiting basal and
insulin-stimulated de novo lipogenesis, but stimulating oxidation of
glucose and free fatty acids.
Although the studies described above demonstrate that leptin can
stimulate lipolysis, this effect may be small comparedwith the lipolytic
activity of adrenergic receptor agonists. In 1997, Fruhbeck et al. [90]
reported that leptin directly stimulated lipolysis in adipocytes isolated
from fasted wild type or ob/obmice. The response was exaggerated in
cells from ob/ob mice compared with lean wild type mice and cells
from dbLepr/dbLepr mice which do not express the long-form leptin
receptor [41] were unresponsive. A maximal response was induced in
cells from wild type mice with the lowest dose of leptin tested which
was below that found in the circulation (0.16 ng/ml). This represented
a 28% increase in glycerol release, which was small compared with the
300% stimulation induced by the adrenergic agonists isoproterenol or
epinephrine. Others [112] reported a weak effect of leptin on glycerol
release from fat cells taken from different fat depots of young or adult
Sprague Dawley rats, requiring as much as 1 μM (16,000 ng/ml) leptin
to produce a signiﬁcant, threefold stimulation. The increase in lipolysis
of isolated cells exposed to low concentrations of leptin, compared
with those that are incubated in media totally devoid of leptin suggests
that under normal conditions leptin contributes to basal triglyceride
turnover, but the failure of higher doses to increase lipolysis in cells
from wild type mice brings into question whether leptin can produce
an acute increase in lipid mobilization through a direct action on fat
cells. A more substantial increase in lipolysis has been reported for
intact fat pads exposed to leptin in vitro, which may imply that para-
crine factors released from non-adipocytes contribute to leptin-
stimulated lipolysis [113].
All of the experiments described above involved a short exposure of
adipocytes to leptin which lasted only a couple of hours, but a failure
of leptin to change basal rates of lipolysis also has been reported for
isolated adipocytes exposed to leptin for as long as 15 h. With this
longer exposure leptin did reverse insulin inhibition of isoproterenol-
stimulated lipolysis [89]. The small effect of leptin on non-stimulated
lipolysis is not limited to cells isolated from rodents as similar results
have been reported for ovine [114] and human adipocytes [62,115].
High doses of leptin (50–150 ng/ml) stimulated lipolysis in porcine
adipocytes [116] or 3T3 L1 cells [117] that were differentiated in cul-
ture, but there was no effect of 5 ng/ml leptin on 3T3-L1 cells during
either a 48-hour or 14-day exposure [117].
The studies described above measured only glycerol release as the
index of lipolysis, but Wang et al. [103] examined the effect of leptin
on both glycerol and free fatty acid release from adipocytes isolated
from lean Zucker rats. They found a small effect on glycerol release
from the cells that was similar to that reported in the previous studies
and that plateaued once leptin in the media exceeded 20 ng/ml, but
also reported that free fatty acids were not released from the fat
cells. These results have since been conﬁrmed using higher doses of
leptin with primary cultures of porcine adipocytes [118] in which
the increase in lipolysis was associated with an increase in adipose
triglyceride lipase (AGTL), an enzyme that is critical for the initial stages
of triglyceride hydrolysis. The increase in glycerol release was also
accompanied by an upregulation of cellular enzymes required for fatty
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unique type of lipolysis in which the fatty acids were oxidized within
the cell. These observations are the opposite to those that would be
expected if leptin selectively released fatty acids hydrolyzed from
triglycerides as reported by Ceddia [105], but the time course of the
two studies was different in that Wang et al. [103] examined fatty
acids release over a period of 6 h and Ceddia's study [105] involved a
15-hour incubation. It is possible that fatty acids released by hydrolysis
of triglycerideswere re-esteriﬁed, consistentwith the report byWilliam
et al. [110] that adipocytes exposed to leptin for 6 h showed increased
fatty acid esteriﬁcation in addition to hydrolysis of triglycerides. The
strain of rat was different for each study and it is possible that the age
of the animals was also different because Ceddia [105] used young
animals, but Wang et al. [103] did not report the age or size of their
animals.
2.3. In vivo evidence for direct effect of leptin on adipocyte metabolism
The in vitro studies described above provide evidence for a direct
effect of leptin on adipocyte metabolism, but in vivo studies suggest
that the impact on body fat mass that these changes would produce is
small compared with the indirect effect of leptin on tissue metabolism.
Development of mice in which leptin receptor expression is selectively
deleted in wild typemice, or selectively expressed in db3J/db3Jmice that
do not express any functional leptin receptor [119] provide conﬂicting
data on whether, or not, expression of leptin receptors in fat is essential
for control of body fat mass. Down-regulation of both long- and short-
form leptin receptors exclusively in white fat with antisense RNA
increased weight gain, doubled body fat mass and induced insulin
resistance in wild type mice [66] implying an important role for these
receptors in themaintenance of energy balance. The increased adiposity
was attributed to the down regulation of β-adrenergic receptors on
adipocytes and appeared to be associated with a decline in energy ex-
penditure because food intake was not changed and body temperature
was reduced. Contrary to these results, deletion of only the long-form
leptin receptor from all peripheral tissues had no effect on the body
composition or metabolic state of mice [120] although it did result in
hyperleptinemia, presumably due to a failure of leptin to down-
regulate its own production by adipocytes. A simultaneous increase in
the amount of leptin bound to the ObRe resulted in no net change in
the concentration of free leptin in the circulation [120]. By contrast, a
high level of expression of ObRb in neural tissue with some low level
of expression in adrenals testes and white fat of db3J/db3J almost
normalized the body composition of male, but not female mice and
diabetes was reversed in both sexes [121]. Similarly, selective removal
of ObRb from neural tissue resulted in obesity and diabetes, but did
not affect fertility or cold tolerance of mice [122,123]. The discrepancy
in the outcomeof the studies that used different technologies to remove
or express receptors, is difﬁcult to explain based on evidence for a crit-
ical role for long-form leptin receptors in mediating leptin activity
[41,124] and leptin's effects on energy balance [47]. One possibility is
that the down-regulation of β-adrenergic receptors in adipocytes of
mice in which leptin receptors were knocked down with antisense
RNA decreased sympathetic tone and that this indirectly caused the
enlargement of the fat depots [125–127]. A role for leptin modifying
adipocyte metabolism via short-form leptin receptors cannot be entire-
ly excluded because Bates et al. [128] reported that 10 nM (160 ng/ml)
leptin produced a rapid onset short-lived stimulation of glucose uptake
that was initiated within 10 min, but lost after 4 h in cultured muscle
cells that do not express ObRb via a PI3K-dependent mechanism. The
extreme obesity of dbLepr/dbLepr mice which express short-form, but
not the long-form leptin receptors [41], however, makes this possibility
unlikely.
Fat transplantation is an alternate in vivo technique that provides
some insight into the relative importance of leptin acting directly to
inﬂuence adipocyte metabolism. The classic transplant studies byAshwell's group found that small pieces of fat from wild type or
ob/obmice transplanted under the kidney capsule took on the pheno-
type of their host [129,130]. Because ob/obmice do not express leptin,
but their fat cells express leptin receptors and wild type mice express
leptin, the results from these studies could be interpreted as leptin
inhibiting lipid accumulation in adipocytes. More recent studies,
however, have involved the transplant of cells from dbLepr/dbLepr
mice into wild type mice. Guo et al. [131] found that the morphology
of adipocytes that developed from stromal vascular cells obtained
from inguinal fat of dbLepr/dbLepr mice transplanted into Ncr Nude
mice was indistinguishable from that of adipocytes that developed
from wild type cells and was similar to that of the host animal endog-
enous fat. Because the cells from dbLepr/dbLepr mice do not express the
long-form leptin receptor [41] these data suggest that the direct effect
of leptin from the host animal has little impact on the differentiation
or maturation of adipocyte progenitor cells. The cells obtained from
female donors developed into smaller adipocytes than those from
males [131], which indicates that genetic inﬂuences over fat cell
development were detectable if they were present.
3. Evidence for an indirect effect of leptin on adipocytes function
through modiﬁcation of insulin action
3.1. Leptin and insulin secretion
The interaction between leptin and insulin occurs atmultiple levels in
that prolonged exposure to insulin stimulates leptin expression [40,132],
leptin directly inhibits insulin secretion from the pancreas, but leptin also
is required for normal whole animal insulin sensitivity [133]. Soon after
the discovery of leptin, both long and short-form leptin receptors were
identiﬁed in pancreatic beta cells and it was determined that leptin
inhibits insulin secretion [134]. Since then it has been reported that
pancreatic beta, delta and alpha cells express long-form leptin receptors
[135,136], but the impact of leptin on beta cells continues to receive the
most attention in terms of pancreatic function. Consistentwith the inhi-
bition of circulating concentrations of insulin in leptin-treated rats and
mice, physiological concentrations of leptin inhibit insulin secretion
from beta cells [137] by opening ATP-sensitive potassium channels
and lowering intracellular calcium concentrations [138]. Leptin has
also been shown to inhibit glucose transport into isolated beta cells
and this lack of stimulation may also contribute to disruption of normal
functioning of the ATP potassium channels that is observed with phys-
iologic concentrations of leptin (10 ng/ml) [139].
In addition to inhibiting insulin secretion leptin inhibits insulin
synthesis by down-regulating mRNA expression of preproinsulin
through a transcriptional mechanism that may involve STAT 5b [140].
Changes in insulin secretion are associatedwith changes in lipidmetab-
olism within the beta cells. Both in vivo and in vitro experiments show
that high concentrations of leptin induce fatty acid oxidation and inhibit
lipogenesis in pancreatic islets, possibly due to increased expression of
uncoupling protein 2 [141]. In leptin resistant animals, the resulting
increase in triglyceride content of islets and development of lipotoxicity
may contribute to their hyperinsulinemia [142]. The relevance of
leptin's inhibition of insulin secretion has been illustrated by an acute
hyperglycemic clamp, leptin dose–response study which showed that
physiologic concentrations (serum leptin = 6 ng/ml) of leptin pro-
duced a 70% suppression of glucose-stimulated insulin secretion [143].
The inhibition of insulin secretion was apparent as early as 20 min
after the start of infusion with this low dose of leptin and as early as
10 min earlier with a high dose leptin infusion (serum leptin =
261 ng/ml). The ratio of glucose infusion rate to insulin concentration
did not change during the clamp, indicating that leptin did not have
an insulin-like effect on glucose uptake during the 2-hour experiment
[143]. The importance of leptin receptor control of beta cell function in
vivo has also been illustrated by the development of hyperinsulinemia
in mice in which the leptin receptor was selectively deleted from
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the development of insulin resistance [144].
3.2. Leptin and whole animal glucose metabolism
One of the ﬁrst papers showing a signiﬁcant effect of leptin on
food intake and body weight also reported that the diabetes of leptin
deﬁcient ob/obmice was corrected by a lower dose of leptin than was
needed to correct energy balance [145]. The correction of
hyperinsulinemia in ob/ob mice could not be simply explained by
inhibition of insulin secretion because blood glucose was also normal-
ized [94,145]. This effect is the opposite from that which would be
expected given observations that leptin inhibits insulin-stimulated
glucose metabolism in adipocytes [89]. Subsequent studies have iden-
tiﬁed tissue-speciﬁc changes in glucose metabolism in responses to
leptin administration. A 5-hour icv or intravenous infusion of leptin
increased whole animal glucose turnover and glycolysis, decreased
liver glycogen content, but increased muscle glucose uptake and
glycogen content in C57Bl/6J mice [96]. These changes in glucose
metabolism were assumed to be mediated by central mechanisms
because the response to leptin was exaggerated in icv infused mice
compared with those receiving intravenous infusions [96]. Similarly,
subcutaneous infusion of 0.5 mg leptin /kg/24 h for 8 days raised
serum glucose concentration to 38 ng/ml, increased whole animal
insulin-stimulated glucose uptake by peripheral tissues and exaggerated
the inhibition of hepatic glucose production by insulin in rats. The inhi-
bition of hepatic glucose output was due to a selective blockade of
glycogen breakdownwith no change in gluconeogenesis [146]. Glucose
metabolism in adipose tissue was not measured in these studies, but
because leptin reduced the size of fat depots in the leptin-infused rats
[146] it can be assumed that the increase in tissue glucose uptake was
limited to muscle and did not involve adipose tissue. Recent experi-
ments with genetically engineered mice suggest that hypothalamic
proopiomelanocortin (POMC) expressing neurons mediate the central
effect of leptin on glucose metabolism. Selective replacement of leptin
receptors in cells that express POMC in dbLepr/dbLepr mice inhibited
hepatic glucose production without changing food intake or correcting
body composition [147].
The critical association between leptin and normal whole animal
glucose metabolism is illustrated by the severe hyperinsulinemia and
hyperglycemia that are present in lipoatrophic animals and humans
that have very little body fat and therefore do not produce signiﬁcant
levels of leptin. There are also several forms of lipodystrophy in which
anabnormal distribution of adipose tissue is associatedwith abnormally
low circulating concentrations of leptin, hyperinsulinemia, insulin
insensitivity and hepatic steatosis. Transgenic mouse models of
lipoatrophy have been developed in which transcription factors
required for lipid synthesis have been either truncated [133] or
inactivated [148]. Leptin replacement in lipoatrophic mice that have
little body fat reverses hyperglycemia and hyperinsulinemia [133,149].
In addition, transplantation of white fat from wild-type mice that
express leptin will correct the hyperinsulinemia and hyperglycemia
[150], whereas fat from leptin-deﬁcient ob/ob mice does not [151].
The correction of insulin sensitivity is associated with restoration of
insulin-induced activation of the insulin receptor and increased insulin
receptor substrate 2 (IRS-2) associated PI3K in the liver [152]. Leptin re-
placement therapy has been used to treat patients with lipodystrophy
because it improves insulin sensitivity, hepatic steatosis and reduces
body fat mass [153]. In patients with lipoatrophy leptin improves
hyperinsulinemia, hyperlipidemia and fatty liver [154,155] within
7 days of starting treatment [155] and allows children to achieve nor-
mal puberty [156].Many of the beneﬁcial metabolic responses observed
in lipoatrophic patients are likely to be secondary to the normalization
of blood glucose and reduction in muscle and liver lipid content that
results from leptin suppressing appetite. In one study 3 months of leptin
treatment reduced energy intake of lipoatrophic patients by 50%without producing any signiﬁcant change in energy expenditure
[157]. However, the early (7 days) normalization of blood glucose and
triglycerides reported by Ebihara et al. [155] leaves open the possibility
that leptin acts directly on insulin-responsive tissues to reverse meta-
bolic abnormalities in lipoatrophic individuals.
3.3. Insulin-like effect of leptin
Even though there is substantial evidence that leptin suppresses
insulin release, it is also clear that lean animals treated with leptin
remain insulin responsive and maintain normal blood glucose con-
centrations [158]. The apparent increase in insulin responsiveness
may be attributed to the loss of fat in these animals, but there also
have been a number of studies that suggest that leptin has an insulin-
like effect. The most dramatic of these are demonstrations that leptin ad-
ministration cannormalize blood glucose in rats that are hypoinsulinemic
and hyperglycemic following treatment with streptozotocin (STZ) which
is toxic to pancreatic beta-cells and results in insulin-deﬁcient diabetes.
This was ﬁrst reported in 1999 [159] when it was demonstrated that a
continuous peripheral infusion of a high dose of leptin from a subcuta-
neous Alzet pump reduced food intake of the diabetic rats by 50%, blood
glucose by 75%, hepatic glucose production by 70% and improved insu-
lin sensitivity. Similar responses have been reported for rats receiving
3rd ventricle infusions [160] or daily lateral ventricle injections of leptin
[161]. Leptin suppressed fasting blood glucose in both control and STZ
rats to levels that were signiﬁcantly lower than in vehicle injected
normoglycemic animals and suppressed fasting insulin concentrations
in control rats to levels that were similar to those in STZ rats. The
improvement in insulin sensitivity was not due to a decrease in food
intake of the leptin-treated rats because pair-fed animals remained
hyperglycemic and insulin insensitive [160,161]. In addition because
both central leptin injections and STZ-treatment reduced serum leptin
concentrations, the changes in glucose metabolism could not be attrib-
uted to a direct effect of leptin on insulin-responsive peripheral tissues.
This has recently been conﬁrmed by a report that peripherally adminis-
tered leptin corrected blood glucose and improved insulin sensitivity in
STZmice that had a liver-speciﬁc deletion of leptin receptors [162]. Sys-
temic treatment of rats with guanethidine, which depleted peripheral
tissue norepinephrine content by 60%, did not prevent the normaliza-
tion of blood glucose in STZ rats receiving central injections of leptin
[163], suggesting that the response was independent of activation of
the sympathetic nervous system.
The long-term effect of leptin on glucose homeostasis was further
investigated in a study in which insulin-deﬁcient non-obese diabetic
(NOD) mice were treated with adenovirus to over-express leptin.
High circulating concentrations of leptin initially normalized blood
glucose, but this effectwaspartially reversed after 3 weeks [164]. Leptin
over-expression also was effective in correcting the diabetes in STZ rats.
It was found that leptin stimulated release of IGF-1, which had insulin-
like effects on muscle, but not liver tissue [164]. Hyperleptinemia also
suppressed glucagon secretion and it appeared that this may be a pri-
mary mediator of the correction of diabetes in the insulin-deﬁcient an-
imals [164]. Recently it has been reported that knockout of the glucagon
receptor prevents development of Type 1 diabetes in STZ-treated mice
[165] which is consistent with evidence that leptin down-regulates
glucagon in vivo in type 1 diabetic mice [164] and that physiological
concentrations of leptin depolarize alpha cells and suppress glucagon
secretion [166].
4. Sympathetic nervous system control of adipose tissuemetabolism
4.1. Sympathetic innervation of white adipose tissue
It is now well established that white adipose tissue receives sympa-
thetic innervation from a complex central network that includes
leptin-responsive areas of the forebrain (including the hypothalamus),
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from the brain to white fat appears to be a primary controller of adipo-
cyte lipolysis [167] due to the release of norepinephrinewhich activates
β-adrenoreceptors and stimulates lipolysis [168]. In addition to its
metabolic impact, sympathetic activation inhibits fat cell proliferation
[125–127] and has the potential to change the size of fat depots due
to a change in cell number. Central administration of leptin has been
reported to increase sympathetic drive to the lumbar and renal system
[169] and intrascapular brown adipose tissue (IBAT) [170], with the
control of sympathetic drive to each of these tissues initiated in differ-
ent areas of the brain [84,171]. A role for melanocortin receptors has
been identiﬁed for the effect of leptin-induced renal and lumbar sympa-
thetic activation [172], but not leptin-induced sympathetic activation of
IBAT [173]. This is surprising given the high percentage of sites that con-
tribute to the sympathetic outﬂow to brown adipose tissue that express
bothmelanocortin 4 and leptin receptors, including the arcuate nucleus
and ventromedial nucleus of the hypothalamus and the nucleus of the
solitary tract and area postrema in the brain stem [57,174].
4.2. Leptin activation of sympathetic efferents to white fat
The importance of sympathetic efferents in mediating leptin's
effects on white adipose tissue is less well deﬁned. It is clear that
central administration of leptin leads to a loss of fat that is maintained
even when food intake is normalized [175], but experiments in which
white fat depots are denervated suggest that the loss of fat is not
dependent on sympathetic drive to the tissue. In experiments in
which we denervated one white fat depot in rats or mice that received
two week peripheral infusions of leptin that doubled circulating leptin
concentrations denervation did not prevent a leptin-induced reduction
in fat depot size, but did prevent the increase in adipocyte proliferation
that was evident in rats with denervated fat pads [126]. In another
study we tested the effects of central and peripheral leptin on norepi-
nephrine turnover (NETO) as a neurochemical measure of sympathetic
activity in various white fat depots of rats. Although it was clear that
leptin could increase NETO in some, but not all, fat depots there was no
correlation between norepinephrine turnover and decrease in fat pad
size [176]. Similarly, Unger's group [177] has reported that adenovirus-
induced hyperleptinemia reduces the size of denervated fat pads. In
those rats the circulating concentrations of leptin were substantially
elevated, but little of this leptin was present in cerebrospinal ﬂuid lead-
ing to the conclusion that leptin must exert its effect on fat metabolism
through mechanisms that are independent of hypothalamic activation
[177].
4.3. Leptin and the sympathetic control of adipocyte metabolism
Even though the denervation studies do not show a clear association
between leptin-induced increases in sympathetic drive to white fat
depots and leptin-induced changes in the size of these depots, Buettner
et al. [178] reported a detailed study examining the effect of infusing
leptin directly into the arcuate nucleus (approximately 200 ng over
6 h) onmultiple parameters of metabolism in epididymal and perirenal
fat depots. Circulating glucose and insulin were clamped to isolate the
effect of leptin from the indirect inﬂuence of leptin on insulin release
and action. Leptin infusion caused a signiﬁcant reduction in lipogenesis
and fatty acid uptake, increased phosphorylation of hormone sensitive
lipase and presumably increased lipolysis, but did not change adipocyte
AMPK which is an index of cellular energy status. The suppression of
lipogenesis was associated with inhibition of the transcription factor
SREBP1 and the nuclear receptor PPARγ, which regulate expression of
lipogenesis enzymes [179,180]. Interestingly the impact of central
leptin on lipogenesiswas independent of hypothalamic STAT3 signaling,
but required activation of PI3K. It also was shown to be dependent upon
sympathetic innervation because surgical denervation or chemical abla-
tion of catecholaminergic neurons with 6-hydroxydopamine (6OHDA)in epididymal fat prevented the effect of leptin on lipogenesis, enzyme
levels and HSL phosphorylation and facilitated an enlargement of the
depot.
Obviously the results of the study by Buettner [178] do not corre-
late with our report of a dissociation between leptin-induced changes
in fat pad NETO and fat pad weight [176]. An important consideration
is which fat depot was examined because epididymal was one of the
fat depots that did show a leptin-induced increase in NETO and a
decrease in fat pad size [176]. Perirenal fat was not examined in our
study [176], but it is a white fat depot that includes a large amount
of brown adipose tissue and it would not be unreasonable to assume
that perirenal brown fat receives leptin-responsive sympathetic
innervation similar to that in IBAT. It would be interesting to know
whether hypothalamic infusion of leptin changes adipocytemetabolism
in intact or denervated inguinal or retroperitoneal depots as these fat
pads decreased in size with central administration of leptin, but did
not show any increase in NETO [176]. If leptin-dependent central
control of adipocytemetabolism is depot speciﬁc, then the translational
relevance of responsiveness in epididymal fat also needs to be evaluated
because humans do not have a direct equivalent of this fat depot. A
point of interest in the Buettner study [178] is that central leptin
increased adipocyte STAT3 phosphorylation and interleukin-6 (IL6)
expression, suggesting that the effects of central leptin on adipocyte
metabolism may be more complicated than increased sympathetic tone
modifying levels of lipogenesis and lipolysis because IL6 interferes with
insulin signaling [181], possibly by increasing SOCS3 expression [101].
Consistent with the data from Buettner's study [178], Shen et al.
[182] reported a signiﬁcant, 50% increase in activity of sympathetic
nerves that innervate epididymal fat in rats that received an intrave-
nous injection of 10 μg of leptin. There was a 20-minute delay between
injection of leptin and increased activity of the nerves and the response
could be blocked by central anti-histamine or by making lesions of the
suprachiasmatic nucleus (SCN), a site that has been shown to send
sympathetic projections to white adipose tissue [183], but has not
been reported to express leptin receptors [57,184]. The increase in
epididymal fat sympathetic outﬂowwas accompanied by a 60% increase
in circulating concentrations of glycerol and free fatty acids that lasted
for at least 2 h. The simultaneous release of fatty acids with glycerol
conﬁrms that the increase in lipolysis was not a direct effect of leptin
if leptin induces a condition in which only glycerol is released from fat
cells following the breakdown of triglycerides [103].
5. Leptin and adipocyte growth and development
In addition to producing direct and indirect effects on adipocyte
metabolism which lead to a reduction in adipocyte size, leptin has the
capability to modify adipose tissue mass by inﬂuencing the number of
cells present through the inhibition of preadipocyte proliferation.
Although in vivo studies clearly demonstrate that leptin reduces
body fat mass, high concentrations of leptin stimulate preadipocyte
proliferation in primary adipocyte culture. Proliferation of porcine
preadipocytes was increased in the presence of 1000 ng/ml leptin
[185], whereas a lower dose of 168 ng/ml (10 nM) leptin was required
to increase cell proliferation in rat primary culture [186]. In the latter
experiment, the cell type that responded to leptin was not determined,
but proliferationwas dependent onMAPK [186]. In a subsequent exper-
iment with primary rat adipocyte culture we found a small, but signiﬁ-
cant increase in proliferation of preadipocytes, but not stromal vascular
cells in the presence of 50 ng/ml leptin, whereas higher concentrations
of leptin (250 ng/ml) inhibited proliferation of all cell types [187]. The
difference between studies in leptin concentration that stimulated
proliferation may be explained by the source of leptin or the species
fromwhich the cellswere derived. The amount of leptin that stimulated
proliferation of rat preadipocytes is in the range that would be found in
the circulation of genetically obese rats [188] and it is possible that in
conditions of extreme obesity leptin increases preadipocyte number
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of cells exposed directly to leptin, proliferation of both preadipocytes
and stromal vascular cells was inhibited by serum from rats that had
been infused with leptin for 5 days [187]. Leptin concentration in the
serum of the leptin-infused rats was increased from 1.2 to 3.2 ng/ml
and serum was included in the incubation media at 0.25% by volume,
excluding a direct effect of leptin on proliferation. These data suggest
that leptin induces release of a circulating factor that has a potent inhib-
itory effect on proliferation of all cell types present in adipose tissue.
Therefore, in vivo it is likely that increased circulating concentrations
of leptin inhibit enlargement of fat depot size in part by preventing an
increase in cell number.
Fat depot size is determined not only by the number of cells present,
but also by the number of preadipocytes that differentiate into lipid
ﬁlled adipocytes. In two of the cell culture studies described above
leptin had no effect on preadipocyte differentiation [185,187], but in
one experiment leptinwas reported to produce a 30% increase in differ-
entiation [186] that was associated with increased expression of lipo-
protein lipase and peroxisome proliferator-activated receptor gamma
(PPARγ2), a primary regulator of preadipocyte differentiation into
mature adipocytes [189]. In contrast to the results from primary culture
leptin had no effect on proliferation or differentiation of 3T3-L1 cells, a
cell line derived from murine ﬁbroblasts that can differentiate and ﬁll
with lipid under appropriate conditions [190], but did reduce the
amount of triglyceride that accumulated in the cells, consistent with
the expected effect of leptin on mature adipocytes [117]. The previous
experiments suggest that leptin does not inﬂuence the differentiation
of preadipocytes to adipocytes, whereas data from an in vivo experi-
ment suggests that hyperleptinemia can lead to dedifferentiation of
adipocytes [191]. Adenovirus-induced over-expression of leptin caused
a 20-fold increase in circulating leptin, resulted in a loss of visible fat in
rats and was associated with an inhibition of expression of PPARγ and
aP2, both of which are markers of differentiated adipocytes. At the
same time Pref1 expression, a marker of preadipocytes, increasedwith-
out any change in total DNA content of the fat depot. These data imply
not only that the adipocytes had lost their lipid stores, but also had
stopped expressing the proteins that are essential for lipid ﬁlling and
reverted to the phenotype of preadipocytes [191]. Thus, in experimental
conditions high concentrations of leptin can potentially directly and/or
indirectly de-differentiate adipocytes. It is, however, unlikely that this
would occur naturally because production of endogenous leptin should
decrease in parallelwith the reduction in fatmass in a leptin-responsive
animal.
6. Summary
There is ample evidence that administration of exogenous leptin to
leptin-responsive animals inhibits food intake and leads to a reduction
in body fat mass. Although the negative energy balance of the animals
causes secondary changes in metabolism to increase lipid mobilization,
there also is a role for leptin to speciﬁcally modify adipocyte metabo-
lism to inhibit lipid accumulation and promote lipid mobilization.
Because adipocytes express both long and short leptin receptors [60],
there is the opportunity for the hormone to act directly on the cells to
reduce cell size. Evidence from in vitro [110,90] and in vivo studies
[120] suggests that the direct effects of leptin on adipocyte metabolism
make a small contribution to the control of fat mass in vivo. By contrast,
leptin-induced changes in insulin secretion contribute to the normaliza-
tion of circulating concentrations of insulin and peripheral tissue insulin
sensitivity [145]. Although leptin stimulates whole animal glucose up-
take [96], this effect is limited to muscle because prolonged exposure
of adipocytes to leptin results in a loss of insulin sensitivity and an inhi-
bition of insulin stimulated lipogenesis and reversal of insulin inhibition
of lipolysis [89]. Central control of adipose metabolism by leptin is
mediated by the sympathetic nervous system and many of the brain
regions that are involved in the control of sympathetic outﬂow towhite fat also express leptin receptors [57,174]. Leptin-induced sympa-
thetic control of adipocytesmetabolismmay be depot speciﬁc [176], but
there is the potential for neural control of lipolysis, lipogenesis, and cell
proliferation [178]. In addition leptin may modify whole body fat mass
simply by inhibiting cell proliferation through the release of circulating
inhibitors of proliferation [187].
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